Guillain-Barré syndrome is an autoimmune inflammatory demyelinating polyneuropathy disorder in which the patient's immune system damages the peripheral nerves. An infection often initiates the onset of the condition. Guillain-Barré syndrome is hard to study, since it is a rare disease with mechanisms that are not yet fully understood. Because of this, the medical community has yet to come with efficient drugs focused on Guillain-Barré syndrome. Once a drug that delays the progression of the disorder is found, the life quality of patients with Guillain-Barré syndrome can be improved, and the scientific community will gain new insights into autoimmune diseases. With this knowledge, future patients could be saved and experience a reduced amount of trauma. Since the disease can be fatal, it is important to focus future research on Guillain-Barré syndrome.